Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis. by Mishra, Nischay et al.
UC San Diego
UC San Diego Previously Published Works
Title
Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid 
Myelitis.
Permalink
https://escholarship.org/uc/item/2qd4m22b
Journal
mBio, 10(4)
ISSN
2150-7511
Authors
Mishra, Nischay
Ng, Terry Fei Fan
Marine, Rachel L
et al.
Publication Date
2019-08-13
DOI
10.1128/mbio.01903-19
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients
with Acute Flaccid Myelitis
Nischay Mishra,a Terry Fei Fan Ng,b Rachel L. Marine,b Komal Jain,a James Ng,a Riddhi Thakkar,a Adrian Caciula,a
Adam Price,a Joel A. Garcia,a Jane C. Burns,c Kiran T. Thakur,d Kimbell L. Hetzler,e Janell A. Routh,b
Jennifer L. Konopka-Anstadt,b W. Allan Nix,b Rafal Tokarz,a Thomas Briese,a M. Steven Oberste,b W. Ian Lipkina
aCenter for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, New York, USA
bDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
cDepartment of Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA
dDivision of Critical Care and Hospitalist Neurology, Department of Neurology, Columbia Irving University Medical Center, New York, New York, USA
eDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
ABSTRACT Acute flaccid myelitis (AFM) has caused motor paralysis in 560 chil-
dren in the United States since 2014. The temporal association of enterovirus (EV)
outbreaks with increases in AFM cases and reports of fever, respiratory, or gastroin-
testinal illness prior to AFM in 90% of cases suggest a role for infectious agents.
Cerebrospinal fluid (CSF) from 14 AFM and 5 non-AFM patients with central nervous
system (CNS) diseases in 2018 were investigated by viral-capture high-throughput
sequencing (VirCapSeq-VERT system). These CSF and serum samples, as well as mul-
tiple controls, were tested for antibodies to human EVs using peptide microarrays.
EV RNA was confirmed in CSF from only 1 adult AFM case and 1 non-AFM case. In
contrast, antibodies to EV peptides were present in CSF of 11 of 14 AFM patients
(79%), significantly higher than controls, including non-AFM patients (1/5 [20%]),
children with Kawasaki disease (0/10), and adults with non-AFM CNS diseases (2/11
[18%]) (P  0.023, 0.0001, and 0.0028, respectively). Six of 14 CSF samples (43%) and
8 of 11 sera (73%) from AFM patients were immunoreactive to an EV-D68-specific
peptide, whereas the three control groups were not immunoreactive in either CSF
(0/5, 0/10, and 0/11; P  0.008, 0.0003, and 0.035, respectively) or sera (0/2, 0/8, and
0/5; P  0.139, 0.002, and 0.009, respectively).
IMPORTANCE The presence in cerebrospinal fluid of antibodies to EV peptides at
higher levels than non-AFM controls supports the plausibility of a link between EV
infection and AFM that warrants further investigation and has the potential to lead
to strategies for diagnosis and prevention of disease.
KEYWORDS VirCapSeq-VERT, acute flaccid myelitis, antibodies, enterovirus,
enterovirus D-68, peptide array, serology
Neurotropic enteroviruses (EVs), such as poliovirus, have long been associated withparalytic disease. While there has been a pronounced decrease in poliomyelitis
cases worldwide due to global polio eradication efforts (1), a similar paralytic syndrome,
acute flaccid myelitis (AFM), has raised concerns that another EV may be implicated (2).
AFM presents with acute flaccid weakness in one or more limbs with depressed tendon
reflexes. Some patients have cranial nerve abnormalities, including facial weakness,
dysarthria, or dysphagia. The majority of affected individuals are children (3). Most
patients report a respiratory, or gastrointestinal illness in the 4 weeks preceding
disease onset. Cases occur in the United States with an every-other-year periodicity
during the late summer and early fall months (www.cdc.gov/acute-flaccid-myelitis/
afm-cases.html).
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The cause of AFM remains elusive. An infectious agent is only rarely detected in
cerebrospinal fluid (CSF). In the initial CDC investigation, the presence of EV RNA by
reverse transcription-PCR (RT-PCR) was demonstrated in the CSF from only 1 of 55
children with confirmed AFM. However, more than 40% of children with AFM had PCR
evidence of EV RNA in respiratory or fecal samples, suggesting a possible role for EV in
AFM (4). Failure to detect viral RNA in CSF by PCR may represent absence of virus, low
levels of viral template, or sequence mismatch between viral template and primers or
probes. Unbiased high-throughput sequencing can address the challenge of sequence
mismatch; however, it is less sensitive than real-time PCR because abundant host RNA
competes with viral RNA in sequencing reactions. Another alternative is the VirCapSeq-
VERT, a positive-selection high-throughput sequencing system that detects viral ge-
netic material with sensitivity equivalent to real-time PCR (5). A third alternative is to
focus on immunological responses to pathogens that may not be present in the
materials sampled (6, 7). In this study, we used both viral-capture high-throughput
sequencing (VirCapSeq-VERT system) and peptide microarray approaches to examine
the role of EV in AFM, using specimens collected from AFM patients and three control
groups of patients with either non-AFM central nervous system (CNS) or inflammatory
illnesses.
RESULTS
Samples from 14 confirmed AFM patients were analyzed (Table 1). With the excep-
tion of one adult, all were pediatric patients with a median age of 3 years (range, 1 to
7 years); 69% were male. The median age for the AFM group was 3 years, compared to
11 years for patients in the non-AFM CNS disease control group (NAC), 0.5 year for
patients in the Kawasaki disease control group (KDC group), and 46 years for adults
with non-AFM CNS diseases (adult control [AC] group) (P  0.0098, 0.0001, and
0.0001, respectively) (Table 1; see Text S1 in the supplemental material). The 14 AFM
and 5 NAC specimens from 2018 were collected in a similar period (AFM, weeks 8 to 38;
NAC, weeks 26 to 37; P  0.6317, Mann-Whitney test) (Text S1). Whereas KDC speci-
mens were collected between 2005 and 2019, AC specimens were collected in 2018.
Virologic testing and VirCapSeq-VERT. Virologic testing was performed on all CSF
samples from AFM and NAC cases, as well as fecal and respiratory specimens (Table 1).
EV-A71 was identified in CSF and feces of 1 of 14 (7%) AFM cases. One of 5 (20%)
non-AFM cases was positive for echovirus 25 (E-25) in CSF, respiratory, and fecal
samples (Table 1). Seven of 14 (50%) AFM cases and 2 of 6 (33%) non-AFM cases were
positive for EV in corresponding respiratory and/or fecal specimens (Table 1).
VirCapSeq-VERT sequencing yielded approximately 320 million single-end reads.
Host subtraction removed 88.7% of the reads, resulting in approximately 36 million
reads for further analysis. De novo assembly yielded approximately 271,000 assembled
contiguous sequences (contigs) and 9.7 million unique sequence reads (singletons).
NCBI nucleotide BLAST analysis enabled assignment of 10,623 contigs and 4.9 million
singletons to viruses. The control CSF specimens containing wild poliovirus type 1
yielded 65 and 29 reads for poliovirus, with genome recovery up to 60.7%. EV-A71 and
E-25 (in samples AFM-07 and non-AFM-16, respectively) identified by PCR and Sanger
sequencing were also detected by VirCapSeq-VERT. We did not detect reads for viruses
other than EV in CSF samples. For samples AFM-07 and non-AFM-16, VirCapSeq-VERT
produced 16,994 and 58,206 EV reads, respectively, comprising 99.0% and 74.8% of
their genomes (Table 2). Complete viral genomes (GenBank accession no. MK800119
and MK800121) were recovered through gap-filling PCR and amplification of the 5= and
3= untranslated regions (UTRs).
EV real-time PCR. Approximately 11,000 and 270 copies of EV RNA were present
per ml of cerebrospinal fluid in AFM-07 and non-AFM-016, respectively (Table 2).
Development of AFM-SeroChip-1 and high-density peptide microarray analy-
ses. We searched for indirect evidence of CNS infection through antibody surveys of
CSF and sera using a programmable peptide microarray based on the Roche Nimblegen
platform (6, 7). This design, the AFM-SeroChip-1, comprised 160,000 unique 12-mer
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peptides with 11 overlapping amino acids (aa) that span the capsid proteins (VP1, VP2,
VP3, and VP4) of all human EVs (species EV-A, EV-B, EV-C, and EV-D) and the polyprotein
of all West Nile viruses (WNVs), using sequences available from the National Center for
Biotechnology Information (NCBI) through 31 January 2019 (Table 3; see Table S1 in the
supplemental material). The AFM-SeroChip-1 also contains 1,000 random 12-aa pep-
tides to detect nonspecific binding.
Fourteen CSF samples from AFM cases and 27 CSF samples from the 3 control
groups (NAC, KDC, and AC) were tested for IgM and IgG antibodies to EV and WNV
using AFM-SeroChip-1. Sera were available for testing from only a subset of these 14
subjects (Table 1). CSF samples from the 14 individuals with AFM and 6 members of the
NAC group were also tested on arrays that detect antibodies to 8 tick-borne pathogens
present in the United States, including Anaplasma phagocytophilum (agent of human
granulocytic anaplasmosis), Babesia microti (babesiosis), Borrelia burgdorferi (Lyme dis-
ease), Borrelia miyamotoi, Ehrlichia chaffeensis (human monocytic ehrlichiosis), Rickettsia
rickettsii (Rocky Mountain spotted fever), Heartland virus, and Powassan virus (7).
Antibodies to WNV and tick-borne pathogens were surveyed due to community
concerns that these agents might be implicated.
Identification of immunoreactive conserved peptides in the VP1 capsid pro-
teins of enterovirus (EV-A to EV-D). High-density peptide microarrays were used to
detect immunoreactivity against a comprehensive EV capsid proteome. We identified
an 18-aa region (7 overlapping 12-mer peptides from each EV species) (Fig. 1) in the
VP1 capsid proteins of EV-A, EV-B, EV-C, and EV-D that was immunoreactive with both
serum and CSF from AFM patients (Fig. 2; see Fig. S1 in the supplemental material). This
region is highly conserved among EVs and is typically used to infer broad EV immu-
noreactivity (8, 9). It includes the motif PALXAXETG, with the exception of EV-D, where
PSL is substituted for PAL (Fig. 1). CSF samples from 11 of 14 AFM patients (79%) were
immunoreactive to this region, compared to those from only 1 of 5 (20%) NAC patients,
0 of 10 (0%) KDC children, and 2 of 11 (18%) AC patients (P 0.023, 0.0001, and 0.0028,
respectively).
One CSF sample from a member of the NAC group, who had an acute CNS infection
with E-25, was also immunoreactive to this conserved EV region (Tables 1 and 2).
Antibodies to EV peptides were found in CSF from 2 of 11 AC patients (NC-A-25 and
TABLE 2 Characteristics of enteroviruses recovered from CSF samples using VirCapSeq-VERT
Sample
no. Status
No. of reads
EV genomic
length (bp)
Polyprotein bp
position
(aa length)
Accession
no.
% genome
coverage
Closest neighbor
(accession no.)
% identity
Real-time PCR
result (copies/ml)Raw Mapped nt aa
AFM-07 AFM 3,880,269 6,994 7,412 748–7309 (2,194) MK800119 99.00 EV-A71 (KU641501.1) 99.00 99.50 11,600
AFM-16 Non-AFM 17,812,593 58,206 7,423 744–7328 (2,195) MK800121 74.80 E-25 (HM031191.1) 86.30 97.90 267
TABLE 3 Overview of high-density peptide microarray (AFM-SeroChip-1) peptide componentsa
Protein name
Total no. of protein
sequences
Redundant protein
clustering criterion
No. of nonredundant 12-aa
peptides with 1-aa offset
Subtotal Total
EV (A–D)_all_ capsid (VP1, VP2, VP3, VP4) 3,532 100%
156,425
EVA_Cap_100 1,341 100% 39,173
EVB_Cap_100 750 100% 63,616
EVC_Cap_100 1,076 100% 46,261
EVD_Cap_100 365 100% 7,375
WNV_polyprotein 5 100% 5,311
Ref-Seq-All-EV (A–D) capsid (VP1, VP2,
VP3, VP4)
25 100% 5,256
Random scrambled nonspecific peptides 100% 1,000
Total no. of unique 12-mer peptides 160,000
aShading indicates the total number of peptides from each protein when using the AFM-SeroChip-1 microarray. The white section contains all of the components
specifically included in the EV (A-D)_all_capsid data.
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NC-A-30) in an intensive care unit with various non-AFM CNS diseases. One of these 2
adults had unspecified epilepsy; the other had multiple sclerosis (Table 1). No CSF
samples from the KDC group were immunoreactive with any EV peptide (Fig. 2). None
of the AFM or non-AFM patients were antibody positive for West Nile virus or tick-borne
disease agents in the CSF. Of the total sera tested, approximately 90% (11/11 [100%]
AFM, 2/2 [100%] NAC, 6/8 [75%] KDC, and 5/5 [100%] AC patients) were reactive with
one or more EV VP1 peptide sequences (Fig. S1).
Immunoreactivity against an EV-D68-specific VP1 peptide in AFM patients.
Although 70% (18/26) of both AFM and control sera were immunoreactive with at least
one VP1 EV-D conserved peptide (Fig. S1), we identified a 22-aa linear peptide se-
quence in the carboxyl terminus of the EV-D68 VP1 protein that was immunoreactive
only in AFM patients (Fig. 1). In AFM patients, this peptide was immunoreactive with 6
of 14 (43%) CSF samples and 8 of 11 (73%) serum samples (Fig. 3). In contrast, this
peptide was not immunoreactive with CSF or serum samples from 5 NAC, 10 KDC, or
11 AC patients. Statistical analysis indicated differences between AFM versus NAC, KD,
and NC controls for both CSF (P  0.008, 0.0003, and 0.035, respectively) and serum
(P  0.139, 0.002, and 0.009, respectively).
DISCUSSION
Since the summer of 2014, 560 cases of AFM have been confirmed in the United
States. The uncertainty underlying the cause for the majority of AFM cases precludes
important public health interventions such as development of diagnostics, specific
therapy, and preventive measures. Growing evidence suggests that infections with EV,
including EV-D68 and EV-A71, may contribute to AFM (4, 10). A potential link to EV-D68
and EV-A71 was proposed based on (i) the presence of viral RNA in some respiratory
and stool specimens, (ii) the observation that EV-D68 infection can result in spinal cord
infection, necrosis, and paralysis in mice (11, 12), and (iii) the temporal association of
respiratory outbreaks of EV-D68 with outbreaks of AFM (4). However, EVs have only
rarely been detected in CSF of AFM patients (4 of 567 total confirmed cases studied at
the CDC [https://www.cdc.gov/acute-flaccid-myelitis/afm-surveillance.html]).
The potential link to EV, combined with the inability to directly detect its nucleic
acids, encouraged us to search for indirect evidence of EV infection in CSF by testing
for the presence of EV-specific antibodies. Since EV infection is common in children,
traditional immunoassays such as enzyme-linked immunosorbent assay (ELISA) are
impeded by cross-reactivity. Virus neutralization assays are considered the “gold stan-
dard” but are resource intensive and impractical to implement for 100 types of EV.
Accordingly, we employed a microarray system that can simultaneously screen thou-
sands of peptides from all known human EVs with high resolution.
FIG 1 Identification of an immunoreactive peptide sequence region in VP1 protein of reference sequence entries for EV-A, EV-B, EV-C, and EV-D from the
National Center for Biotechnology Information (NCBI). VP1 protein models of RCSB Protein Data Bank (RPD) accession no. 4N53, 1COV, E3J48, and 6CSG were
used to annotate EV-A, -B, -C, and -D, respectively, for the beta sheets (yellow arrows) and alpha helix (purple tubes). Approximate locations of BC and DE loops
are based on analyses by Liu et al. (14) and Imamura et al. (23). Conserved amino acids are highlighted by color. The EV-D68-specific peptide shared less than
70% amino acid identity to other EVs, including EV-D70 and EV-D94.
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Across the entire EV capsid proteome tiled with 160,000 peptides, the conserved EV
VP1 peptides were consistently immunoreactive in CSF of 79% (11/14) of children with
AFM, the majority of whom had no EV RNA in CSF. In comparison, NAC patients without
evidence of EV RNA in any specimen and KDC patients did not have antibodies to EV
peptides in CSF. This conserved peptide region reflects broad EV immunoreactivity,
suggesting an association with EV infection and AFM. It is also consistent with EV
pathogenesis in mouse models, wherein EVs, including EV-D68, can cause paralytic
illness (11, 12).
The demonstration that antibodies to EV peptides are intrathecally produced, such
as using an intrathecal ratio of CSF to sera, would provide stronger evidence of CNS
infection. We do not have access to sufficient numbers of simultaneously collected CSF
and serum specimens to exclude trafficking of EV antibodies from the peripheral
circulation into the CNS. However, we consider this unlikely to explain the presence of
antibodies to EV peptides in CSF of AFM patients. Of 16 control patients who had
antibodies to EV peptides in serum (3 NAC, 8 KDC, and 5 AC patients), only 2 adults and
1 child also had antibodies against EV peptides in CSF. The child with antibodies against
EV peptides in CSF had an active CNS infection, with E-25 detected in the same CSF
sample. One of the 2 adults had multiple sclerosis, and the other had idiopathic
epilepsy. Furthermore, in a study of unexplained encephalitis in Gorakhpur, India, using
FIG 2 Immunoreactivity against VP1 conserved peptide sequences of EV-A, EV-B, EV-C, and EV-D in cerebrospinal fluid samples of patients with AFM, non-AFM
controls (NAC), Kawasaki disease controls (KDC), and adults with CNS diseases (AC). All AFM and NAC specimens were from 2018, except NC-P_76.
Mishra et al. ®
July/August 2019 Volume 10 Issue 4 e01903-19 mbio.asm.org 6
the same peptide array platform, only 3 of 77 children with antibodies to EV in serum
also had antibodies to EV in CSF. Two of these 3 children had diagnoses of EV
meningoencephalitis based on symptoms and EV RNA (coxsackievirus or echovirus) in
their CSF (N. Mishra and W. I. Lipkin, unpublished data).
We demonstrated immunoreactivity to EV-D68-specific peptides (located within the
VP1 C terminus) in CSF from 43% of AFM patients and no immunoreactivity in any of
the CSF samples from NAC, KDC, and AC control groups. Based on structural homology,
the VP1 C terminus of the EV-D68 strain has been predicted to form neutralization
immunogens and conformational epitopes for putative neutralizing antibodies (13, 14).
The same EV-D68-specific peptides were immunoreactive in 8 of 11 (73%) sera from
AFM patients, compared to none from the three control groups (NAC, KDC, and AC).
These findings may appear to be at odds with seroprevalence studies in children and
adults in the United States that indicate near 100% infection rates using neutralization
assays (13, 15). One potential explanation is that neutralization assays may detect
additional nonlinear conformational epitopes, whereas peptide arrays present only
linear epitopes. Reactivity from one peptide region may not be comparable to that of
the neutralization assay using the whole virion. In work with sera from children exposed
to Zika virus, antibodies to the NS2B protein were specific but were not detected at 6
months in 45% of documented infections (6). Understanding why this EV-D68-specific
linear peptide is highly reactive in AFM cases but not in controls may shed light on the
immune response to EV-D68.
Our serological findings warrant further investigation into the association of AFM
with enteroviruses, including EV-D68. Reports of respiratory illness consistent with viral
infection typically occurred several days before onset of weakness in the majority of
AFM cases. Our inability to detect EV-D68 RNA in the CSF of AFM patients may reflect
lack of virus shedding from CNS parenchyma into the intrathecal compartment. Alter-
natively, CSF specimens may have been collected after virus was cleared from the CNS.
An important limitation of our study is that controls were not optimally matched to
the AFM cases with respect to age, year, or season of collection. Although we tried to
test for specificity of findings through use of three control groups, prospective studies
with appropriately matched controls from the same EV outbreak season will be critical
to testing their validity.
FIG 3 Immunoreactivity against an EV-D68-specific 22-aa VP1 capsid peptide in patients with AFM, non-AFM controls (NAC), Kawasaki disease controls (KDC),
and adult CNS disease controls (AC). Respective immunoreactivity intensity measured by the high-density peptide microarrays is shown in heat maps of
overlapping 12-mer peptides in the 22-aa EV-D68-specific VP1. Results are shown for cerebrospinal fluid (CSF) in the upper panel and serum in the lower panel.
The heat map colors indicate descending reactivity from red, to yellow, to blue. Serum samples not available are indicated in gray. All AFM and NAC specimens
were from 2018, except NC-P_76.
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Conclusions. While other etiologies of AFM continue to be investigated, our study
provides further evidence that EV infection may be a factor in AFM. In the absence of
direct detection of a pathogen, antibody evidence of pathogen exposure within the
CNS can be an important indicator of the underlying cause of disease. Our findings
warrant additional investigation, including testing more specimens, developing confir-
matory assays, and designing optimally controlled prospective studies. These initial
results may provide avenues to further explore how exposure to EV may contribute to
AFM as well as the development of diagnostic tools and treatments.
MATERIALS AND METHODS
Virologic testing for AFM surveillance. In 2018, CDC received specimens from 381 patients
suspected to have AFM (https://www.cdc.gov/acute-flaccid-myelitis/afm-cases.html). Classification crite-
ria for a confirmed AFM case are acute flaccid limb weakness and magnetic resonance imaging evidence
of a predominantly gray matter lesion that spans at least one spinal segment (https://www.cdc.gov/
acute-flaccid-myelitis/hcp/case-definition.html) (16). Suspect cases were considered non-cases if they
failed to meet the confirmed case definition or had an alternative diagnosis to explain their symptoms.
As part of diagnostic testing for AFM surveillance, CDC tested CSF, respiratory, and fecal specimens from
suspected AFM cases for EV using a real-time reverse transcription-PCR (rRT-PCR) EV assay (17) and an EV
typing assay by VP1 seminested PCR and Sanger sequencing (8). Specimens were also tested for
parechoviruses using rRT-PCR (18). Respiratory specimens were further tested using an EV-D68-
specific rRT-PCR assay (https://www.fda.gov/medicaldevices/safety/emergencysituations/ucm161496
.htm#enterovirus).
Patients and specimens. For investigation using VirCapSeq-VERT and peptide microarray ap-
proaches, we selected a subset of samples (based largely on available CSF volumes) from AFM cases with
onset in 2018, including 13 children and 1 adult. Three groups of controls (Table 1) are included: (i) 5
patients with non-AFM CNS diseases collected during a similar time period as the AFP cases (non-AFM
CNS control group [NAC] group; all except one were children), (ii) 10 children with Kawasaki disease
(Kawasaki disease control [KDC] group) (19, 20), and (iii) 11 adults with non-AFM CNS diseases (adult
control [AC] group). One additional NAC case from 1 child with autoimmune encephalitis (AC-KT-076)
during 2019 was also included. NAC and AC controls were included to examine the possibility that
antibodies in the peripheral circulation might traffic into the CSF in children and adults with CNS diseases
who may have increased permeability of the blood-brain barrier. Paired CSF and serum samples were
available for 11 children with AFM, 2 children from the NAC group, 8 children from the KDC group, and
5 adults from the AC group. As an internal positive control for VirCapSeq-VERT performance, we included
two RNA extracts from stored CSF specimens of paralytic type 1 wild poliomyelitis cases from Republic
of Congo in 2010 (21).
VirCapSeq-VERT analysis. The VirCapSeq-VERT capture probe library comprises approximately 2
million oligonucleotides that tile the coding regions of genomes for all viral taxa that contain at least one
virus known to infect vertebrates (5). Total nucleic acid was extracted from 240 l of CSF using the
NucliSens easyMAG automated platform (bioMérieux, Boxtel, The Netherlands). Illumina libraries were
prepared, pooled, and hybridized with the VirCapSeq-VERT probe set prior to sequencing (Illumina HiSeq
4000) (5, 22). Human genomic and ribosomal sequences were subtracted, and the remaining sequences
were analyzed for viral sequences using MegaBlast and BLASTX against the GenBank nonredundant
nucleotide and protein databases, respectively.
Assessment of VirCapSeq-VERT efficiency in detection of enterovirus RNA. To determine the
efficiency of VirCapSeq-VERT in EV genome recovery, we quantitated the amount of EV template in CSF
by quantitative reverse transcription-PCR (qRT-PCR). A one-step qRT-PCR assay that targeted a conserved
region within the 5= untranslated region (UTR) was performed on all CSF samples. Ten microliters of total
nucleic acid extract was reverse transcribed using Superscript III (Life Technologies). The qRT-PCR assay
was performed using 2 l of cDNA, EV-F primer (TCCTCCGGCCCCTGAATGYGGCTAAT), EV-R primer
(GGAAACACGGWCACCCAAAGTA), and EV-probe (6-carboxyfluorescein [FAM]-GCAGCGGAACCGACT-
MGB) in a Bio-Rad Touch-CFX 96 real-time PCR instrument at 95°C for 2 min followed by 45 cycles of
qPCR at 95°C for 15 s and 60°C for 1 min.
SeroChip analyses. Samples were diluted in binding buffer (0.1 M Tris-Cl, 1% alkali soluble casein,
0.05% Tween 20, and water) and hybridized on the AFM array overnight (16 h) at 4°C on the flat surface.
After incubation, arrays were washed 3 times for 10 min each on a Little Dipper processor (SciGene;
catalog no. 1080-40-1) with 1 TBST (Tris-buffered saline plus 0.05% Tween 20) at room temperature.
Secondary antibodies were diluted to 1:5,000 in binding buffer at a concentration of 2 g/ml. Secondary
antibody incubation was done in a plastic Coplin jar (Fisher Scientific; catalog no. S90130) for 3 h at room
temperature with gentle shaking on a rocker shaker. First, arrays were incubated with Alexa Fluor 647
AffiniPure goat anti-human IgG that was Fc fragment specific (Jackson ImmunoResearch Labs, Inc.;
catalog no. 109-605-098), followed by three 10-min washes. Then arrays were incubated with AffiniPure
goat anti-human IgM that was Fc5 fragment specific (Jackson ImmunoResearch Labs, Inc., no. 109-
005-043). Incubation with secondary antibody was followed by three 10-min washes with 1 TBST at
room temperature and spin-drying. The array slides were scanned on a NimbleGen MS 200 microarray
scanner (Roche) at a 2-m resolution, with excitation wavelengths of 635 and 537 nm simultaneously. In
the images recorded with the laser scanner, the relative fluorescent unit (RFU) signals for all the probes
were extracted using Roche Sequencing Solutions image extraction software. The RFU signals for all the
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probes were extracted from the images using Roche Sequencing Solutions image extraction software.
The RFU signals were converted into intensity plots after quantile normalization, background and spatial
correction, and deconvolution for redundant peptides. An epitope was considered reactive when the
signal intensity for at least three contiguous 12-mer peptides was above the threshold. The signal
threshold was defined for each reactive epitope by calculating the mean plus 3 standard deviations of
the signal intensity for the same epitope in the negative-control samples.
The array data, in the form of relative fluorescence signal intensities from the scanned images
(arbitrary units [AU]), were spatially and background corrected and quantile normalized. Signal data
points were filtered to retain only immunoreactive peptides that showed the mean 2 standard
deviations (10,000-AU signal for serum and 3,500-AU signal for CSF based on measured values for
reactivity against scrambled nonspecific peptide sequences). A region was considered immunoreactive
when the signal intensity for at least three contiguous 12-mer peptides was above the threshold. The
signal threshold was defined for each immunoreactive epitope by calculating the mean 2 standard
deviations of the signal intensity for the same epitope in negative-control samples (6, 7). Immunoreactive
peptides were compared with a comprehensive EV protein alignment to scan for type-specific signals.
Assessment of immunoreactivity signal intensity from the high-density peptide microarray
among cases and controls. For the EV VP1 conserved peptide and EV-D68-specific peptide sequences,
comparison of immunoreactivity signal intensity between AFM, non-AFM, Kawasaki disease, and adult
CNS groups were evaluated using the Wilcoxon test for paired samples (JMP, v13.0.0; SAS Institute, Inc.,
Cary, NC).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.01903-19.
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